The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

West Tennessee law enforcement officials said that testing by Eli Lilly, the maker of Mounjaro and Zepbound, after the raid revealed that one of the samples sold by Arnold was nothing more than ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.